MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 127255 | Name: Eplivanserin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eplivanserin, also known as SR-46349, is an inverse agonist on the serotonin receptor subtype 5-HT2A. In contrast to older sedating drugs acting on 5-HT2A receptors (e.g., mirtazapine, clozapine, risperidone), eplivanserin has practically no affinity to dopamine, histamine and adrenergic receptors.

Chemical Structure

Eplivanserin
Eplivanserin
CAS#130579-75-8 (free base)

Theoretical Analysis

MedKoo Cat#: 127255

Name: Eplivanserin

CAS#: 130579-75-8 (free base)

Chemical Formula: C19H21FN2O2

Exact Mass: 328.1587

Molecular Weight: 328.39

Elemental Analysis: C, 69.49; H, 6.45; F, 5.79; N, 8.53; O, 9.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
130579-75-8 (free base) 130580-02-8 (fumarate)
Synonym
Eplivanserin; Eplivanserine; Eplivanserina; SR-46349; SR46349; SR 46349;
IUPAC/Chemical Name
(1Z,2E)-1-(2-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one O-(2-(dimethylamino)ethyl) oxime
InChi Key
VAIOZOCLKVMIMN-PRJWTAEASA-N
InChi Code
InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-
SMILES Code
CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)C2=CC=CC=C2F
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 328.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging. 2018 Sep;35(9):791-817. doi: 10.1007/s40266-018-0569-8. PMID: 30058034. 2: Sukys-Claudino L, Moraes WA, Tufik S, Poyares D. Novos sedativos hipnóticos [The newer sedative-hypnotics]. Braz J Psychiatry. 2010 Sep;32(3):288-93. Portuguese. doi: 10.1590/s1516-44462010000300014. PMID: 20945020. 3: Monti JM. Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects. Drugs Today (Barc). 2010 Mar;46(3):183-93. doi: 10.1358/dot.2010.46.3.1437247. PMID: 20467592. 4: Sinh V, Ootsuka Y. Blockade of 5-HT2A receptors inhibits emotional hyperthermia in mice. J Physiol Sci. 2019 Nov;69(6):1097-1102. doi: 10.1007/s12576-019-00703-7. Epub 2019 Aug 20. PMID: 31432430. 5: Griebel G, Beeské S, Jacquet A, Laufrais C, Alonso R, Decobert M, Avenet P, Françon D. Further evidence for the sleep-promoting effects of 5-HT₂A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats. Neuropharmacology. 2013 Jul;70:19-26. doi: 10.1016/j.neuropharm.2012.12.008. Epub 2013 Jan 12. PMID: 23321054. 6: Sanger DJ, Soubrane C, Scatton B. New perspectives for the treatment of disorders of sleep and arousal. Ann Pharm Fr. 2007 Jul;65(4):268-74. doi: 10.1016/s0003-4509(07)90046-2. PMID: 17652996. 7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PMID: 15071612. 8: Teegarden BR, Al Shamma H, Xiong Y. 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76. doi: 10.2174/156802608784936700. PMID: 18673166. 9: Orejarena MJ, Lanfumey L, Maldonado R, Robledo P. Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour. Int J Neuropsychopharmacol. 2011 Aug;14(7):927-40. doi: 10.1017/S1461145710001215. Epub 2010 Oct 14. PMID: 20942998. 10: Harmon JL, Wills LP, McOmish CE, Demireva EY, Gingrich JA, Beeson CC, Schnellmann RG. 5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists. J Pharmacol Exp Ther. 2016 Apr;357(1):1-9. doi: 10.1124/jpet.115.228395. Epub 2016 Jan 19. PMID: 26787771; PMCID: PMC4809314. 11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PMID: 18985183. 12: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):193-219. PMID: 15834452. 13: Boulay D, Ho-Van S, Bergis O, Avenet P, Griebel G. Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: a putative model of the negative symptoms of schizophrenia? Behav Pharmacol. 2013 Oct;24(7):543-51. doi: 10.1097/FBP.0b013e3283654044. PMID: 23928693. 14: Bhyrapuneni G, Thentu JB, Palacharla VRC, Muddana N, Aleti RR, Ajjala DR, Nirogi R. A definite measure of occupancy exposures, seeking with non- radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions. J Recept Signal Transduct Res. 2018 Aug;38(4):359-366. doi: 10.1080/10799893.2018.1531888. PMID: 30481094. 15: Heller HC, Salehi A, Chuluun B, Das D, Lin B, Moghadam S, Garner CC, Colas D. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Neurobiol Learn Mem. 2014 Dec;116:162-71. doi: 10.1016/j.nlm.2014.10.002. Epub 2014 Oct 29. PMID: 25463650.